PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:10PM CST
PTC Therapeutics (PTCT) initiated the process of a rolling submission of a new drug application to the FDA for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PTCT: 51.66 (+0.76), BIOD: 1.36 (-0.04)
PTC Therapeutics begins rolling submission of Translarna's NDA to the US FDA for treating nonsense mutation Duchenne muscular dystrophy
M2 - Wed Dec 24, 3:46AM CST
Biopharmaceutical company PTC Therapeutics (NasdaqGS
PTCT: 51.66 (+0.76)
BioMarin CEO Sees Big Future For Prosensa Drug
at Investor's Business Daily - Tue Dec 23, 3:11PM CST
BioMarin Pharmaceuticals raised a few eyebrows last month when it announced its latest buyout. BioMarin (BMRN) agreed to pay $680 million upfront for Prosensa Holding (RNA), a Dutch biotech developing a drug for Duchenne muscular dystrophy called...
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), PTCT: 51.66 (+0.76), GSK: 42.85 (+0.11)
PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST
ROSG: 2.35 (+0.03), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), PTCT: 51.66 (+0.76)
PTC Therapeutics Begins Rolling NDA Submission to the FDA for Translarna to Treat Duchenne Muscular Dystrophy
PR Newswire - Tue Dec 23, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Translarna(TM) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. PTC expects to finalize the application in the fourth quarter of 2015 following the completion of the ACT DMD confirmatory Phase 3 clinical trial.
PTCT: 51.66 (+0.76)
3 Drugmakers Facing a Pivotal 2015
George Budwell, The Motley Fool - Motley Fool - Mon Dec 22, 10:41AM CST
Source: www.bio.org Pharmaceutical companies have been some of the best performing stocks lately due to the confluence of an aging U.S. population and new regulatory avenues within the Food and Drug Administration that have led to an uptick in drug...
BIIB: 340.89 (+5.13), ISIS: 59.49 (+1.88), GWPH: 68.08 (+1.82), AZN: 70.44 (+0.26), IBB: 299.80 (+5.12), PTCT: 51.66 (+0.76), GSK: 42.85 (+0.11)
PTC Therapeutics (PTCT) Downgraded From Hold to Sell
at The Street - Mon Dec 22, 10:40AM CST
PTC Therapeutics (PTCT) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D+.
PTCT: 51.66 (+0.76)
Translarna tagged an Orphan Drug for MPS 1 in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 12:39PM CST
PTCT: 51.66 (+0.76)
Translarna Granted Orphan Drug Designation in the U.S. and Europe for the Treatment of Mucopolysaccharidosis I
PR Newswire - Fri Dec 19, 7:00AM CST
PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted orphan-drug designation (ODD) to Translarna(TM) (ataluren) for the treatment of patients with Mucopolysaccharidosis I (MPS I). MPS I is an inherited genetic disorder caused by a deficiency in an essential enzyme that is responsible for the breakdown of by-products in the body's cells. There is significant unmet medical need and new treatments targeting the underlying cause of the disease are needed. MPS I represents the third indication for which Translarna has received orphan-drug designation. Translarna also has orphan-drug designation for Duchenne muscular dystrophy and cystic fibrosis.
PTCT: 51.66 (+0.76)
PTC Therapeutics awards stock options to ten new employees under NASDAQ Listing Rule 5635(c)(4)
M2 - Thu Dec 18, 7:12AM CST
Biopharmaceutical company PTC Therapeutics (NasdaqGS
PTCT: 51.66 (+0.76)
Chimerix appoints Ronald C. Renaud Jr to board
M2 - Thu Dec 18, 7:12AM CST
Biopharmaceutical company Chimerix (NasdaqGM:CMRX) revealed on Wednesday the addition of Ronald C. Renaud Jr to its board of directors.
CMRX: 36.80 (+0.70), PTCT: 51.66 (+0.76)
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Wed Dec 17, 3:30PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 15, 2014 it approved non-statutory stock options to purchase an aggregate of 46,750 shares of its common stock to ten new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of its new hires' employment compensation.
PTCT: 51.66 (+0.76)
Pfizer commences Phase 2 study in Duchenne Muscular Dystrophy
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:10AM CST
ROSG: 2.35 (+0.03), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), PTCT: 51.66 (+0.76)
Why PTC Therapeutics (PTCT) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:31AM CST
PTC Therapeutics (PTCT) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 72 out of more than 250 industries.
PTCT: 51.66 (+0.76)
PTC Therapeutics, Inc. (PTCT) in Focus: Stock Gains 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 8:32AM CST
PTC Therapeutics, Inc. (PTCT) was a big mover last session, as the company saw its shares rise more than 5% on the day.
LGI: 16.17 (-0.01), ARQL: 1.15 (+0.01), PTCT: 51.66 (+0.76), IG: 9.11 (-0.01)
PTC Therapeutics Announces Launch of Translarna(TM) (ataluren) in Germany
PR Newswire - Wed Dec 03, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna(TM) (ataluren) is now commercially available to patients in Germany, the first country to launch in the European Union (EU), with first shipments expected to begin this week.
PTCT: 51.66 (+0.76)
PTC Therapeutics (PTCT) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 5:40AM CST
PTC Therapeutics (PTCT) Shares March Higher, Can It Continue?
PTCT: 51.66 (+0.76)
Catabasis Pharmaceuticals' CAT-1004 tagged an Orphan Drug for DMD
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:15AM CST
ROSG: 2.35 (+0.03), BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PTCT: 51.66 (+0.76)
PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award
PR Newswire - Fri Nov 21, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that the 2014 Legend of Technology Award for Vision, Innovation, and Leadership has been awarded to Stuart W. Peltz, Ph.D., Chief Executive Officer. This award recognizes an individual who has had a significant impact on the technology industry in New Jersey for several decades.
PTCT: 51.66 (+0.76)
Spinal Muscular Atrophy Program Enters Phase 1b/2a Trial in Patients with SMA
PR Newswire - Wed Nov 19, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) has started a Phase 1b/2a study in adult and pediatric patients. The placebo-controlled, randomized, multiple-dose study will enroll approximately 48 patients with SMA and investigate the safety and tolerability of an investigational survival of motor neuron 2 (SMN2) gene splicing modifier (RG7800) over 12 weeks. The achievement of this milestone triggers a $10 million payment to PTC from Roche.
PTCT: 51.66 (+0.76)